Cancer patients are expected to benefit from the recent approval by the FDA of the first biosimilar drug to treat various types of cancer. This drug, bevacizumab-awwb, known as Myasi, is the biosimilar of bevacizumab, known as Avastin. While the FDA has approved the use of Myasi as a biosimilar, it is not approved as[...] Read More
